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Abstract The aim of this study is to compare the psycho-
pathology and the quality of life of chronic daily headache
patients between those with migraine headache and those
with tension-type headache. We enrolled 106 adults with
chronic daily headache (CDH) who consulted for the first
time in specialised centres. The patients were classified
according to the IHS 2004 criteria and the propositions of the
Headache Classification Committee (2006) with a computed
algorithm: 8 had chronic migraine (without medication
overuse), 18 had chronic tension-type headache (without
medication overuse), 80 had medication overuse headache
and among them, 43 fulfilled the criteria for the sub-group of
migraine (m) MOH, and 37 the subgroup for tension-type (tt)
MOH. We tested five variables: MADRS global score,
HAMA psychic and somatic sub-scales, SF-36 psychic, and
somatic summary components. We compared patients with
migraine symptoms (CM and mMOH) to those with tension-
type symptoms (CTTH and ttMOH) and neutralised pain
intensity with an ANCOVA which is a priori higher in the
migraine group. We failed to find any difference between
migraine and tension-type groups in the MADRS global
score, the HAMA psychological sub-score and the SF36
physical component summary. The HAMA somatic anxiety
subscale was higher in the migraine group than in the tension-
type group (F(1,103) = 10.10, p = 0.001). The SF36 mental
component summary was significantly worse in the migraine
as compared with the tension-type subgroup (F(1,103) =
5.758, p = 0.018). In the four CDH subgroups, all the SF36
dimension scores except one (Physical Functioning) showed a
more than 20 point difference from those seen in the adjusted
historical controls. Furthermore, two sub-scores were signif-
icantly more affected in the migraine group as compared to
the tension-type group, the physical health bodily pain
(F(1,103) = 4.51, p = 0.036) and the mental health
(F(1,103) = 8.17, p = 0.005). Considering that the statistic
procedure neutralises the pain intensity factor, our data sug-
gest a particular vulnerability to somatic symptoms and a
special predisposition to develop negative pain affect in
migraine patients in comparison to tension-type patients.
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Between 3 and 4% of the general population suffer from
chronic daily headache (CDH) and a quarter to a third of
them suffer from medication overuse headache (MOH)
([1–4], see specific European data in [5]).
Psychopathological correlates of CDH have been
assessed by various means: personality tests, diagnostic
devices, and psychopathologic scales (see reviews in [6–
8]). An approach with MMPI [9] reveals a higher number
of high scores (over 65) in chronic migraine and analgesic
rebound headache patients when compared to episodic
migraineurs. The prevalence of psychiatric disorders is
high in CDH, mostly in anxiety and mood disorders
[10–12]. The use of rating scales confirms this important
psychopathological burden in CDH [12] which was
reported to be higher in patients with medication overuse
[13, 14] who can be considered drug-dependent according
to the DSM-IV definition [15].
When assessed by various scales, the quality of life in
CDH is reduced [12, 16–19], particularly in transformed
migraine patients [17–20]. However, these data are difficult
to be transposed into the more recent actual international
classification of headache disorders (ICHD) [21] which
was completed by the complementary note of the Headache
Classification Committee [22]. However, more studies
based on accepted classifications (ICDH-2 and DSM-IV R)
are needed [23]. Furthermore, recent suggestions have been
made to break out the medication overuse headache group
(code 8.2) [24, 25].
In this study, we address the following question: in the
entire group of patients who have CDH, do patients with
migraine symptoms have a different psychopathology and
quality of life burden than those with tension-type head-
ache? Our analysis studies three well-defined groups of
chronic headache: chronic migraine (CM, code 1.5.1),
chronic tension-type headache (CTTH, code 2.3.2), and
medication overuse headache (MOH, code 8.2). In the last
group, using a special clinical analysis, we divided the
patients into two subsets, those with migraine symptoms
(mMOH) and those with tension-type symptoms (ttMOH).
Method
This study was planned during the year 2000 and patients
were enrolled between September 2001 and July 2002. We
used the CTTH definition of ICHD-II and the proposals of
the Headache Classification Committee (2006) for chronic
migraine (CM) and MOH [22, 23]. Patients who had




We enrolled 106 patients (75 females and 31 males) with a
mean age of 47 years (range 17–83 years, mean
46.9 ± 15.5) who had consulted a neurologist, either in a
liberal office (5 investigators), or in an outward consulta-
tion in an University Hospital (5 investigators),in the West
of France (West Migraine Study Group) for chronic
headache, i.e. headache occurring more than 15 days/
month for more than 3 months, with attacks lasting more
than 4 h when untreated [5]. All patients gave prior,
informed consent as recommended by the Tours University
Hospital ethical committee. Two pre-inclusion investigator
rating sessions were organised in order to homogenise the
evaluations.
Each participating physician filled out a questionnaire
which took into account the characteristics of the head-
ache(s) reported by the patients. An algorithm automati-
cally determined the classification of the headache. Thus, a
given patient could theoretically report several types of
headache and a given headache could receive several dif-
ferent ICHD-II codes. Headache which met criteria for
both probable migraine (PM) (ICHD-II, code 1.6.1) and
tension-type headache (TTH) was classified as TTH
according to rule # 5 of the ICHD-II. In each patient, we
computed the number of days per month he or she suffered
for each type of headache and specified the medications
taken during the last 3 months; when necessary medical
files were used to determine if patients filled ICHD-II
criteria for MOH. The final classification identified 80
MOH patients, 8 chronic migraine (CM) patients, and 18
CTTH patients.
For the needs of the study, MOH patients were divided
into two sub-groups: mMOH and ttMOH.
(1) mMOH, if they also fulfilled the criteria for chronic
migraine (i.e. precisely, code 1.5.1 criteria A, B, and
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C according to the Headache Classification Commit-
tee (2006)) with the exception of drug abuse. We
included patients into this subset who fit the diagnos-
tic of probable migraine, in other words, code 1.1
criteria B or D (IHS classification 2004).
(2) ttMOH, if they fulfilled the diagnostic criteria for
chronic tension-type headache (i.e. code 2.3 A–D
criteria, IHS classification 2004) with the exception of
the drug abuse.
Using this procedure, among the 80 MOH patients
enrolled in the study cohort, 43 were classified in the
mMOH group and 37 into the ttMOH group. It should be
noted that four patients had mMOH between 8 and 15 days
per month in addition to 15 days or more with ttMOH
headache and were consequently classified in the mMOH
group by analogy with the Headache Classification Com-
mittee (2006) position concerning chronic migraine criteria
(code 1.5.1). Furthermore, one patient had mMOH for
5 days and headache with ttMOH characteristics for
12 days and was classified as ttMOH.
Description of the sub-groups
The demographic characteristics of the four sub-groups
included the number of patients in each group, their ages,
body mass index, the age at which they left school, marital
status, and known previous psychiatric disorders and are
summarised in Table 1.
This table also includes the patients’ previous stressful life
events. To this end, we used the Amiel Lebigre [26] ques-
tionnaire, which, according to the author, is constructed from
previous life event scales [27, 28]. Patients were asked to rate
from 1 to 100 the impact of 52 precise stressful life events
(?one open) on their lives. The authors consider that a global
score greater than 200 is suggestive of depression. For the
study, the interviewers asked the patients to focus on the
period during which the headache became chronic.
Finally, we considered the pain intensity factor associ-
ated with the headache, which, a priori, is lower in patients
with tension-type headache (level light or moderate, IHS
criteria 2.1.C), in contrast to patients with migraine head-
ache (level moderate or severe criteria 1.1.C) is may be
used for inclusion. To this end, we established a pain index
composed by the sum of the number of days with headache
multiplied by a semi-quantitative evaluation of the pain
intensity (0 to 3) during these days over last 3 months.
Psychopathological and quality of life scales
1. The tendency for depression was evaluated by using the
Montgomery and Asberg Depression Scale (MADRS)
[29], a commonly used scale derived from the Com-
prehensive Psychiatric Rating Scale which contains 10
items (apparent and reported sadness, inner form,
reduced sleep and appetite, concentration difficulties,
lassitude, inability to feel, pessimistic, and suicidal
thoughts) rated from 0 to 6. A total cut-off score of 15
may differentiate depressive subjects; a score of 20 is
usually required for inclusion into therapeutic trials [30].
2. The severity of the anxiety symptoms was evaluated
with the Hamilton anxiety scale HAMA (Hamilton
anxiety) which consists in 14 items rated from 0 to 4:
anxious mood, tension, fears, insomnia, intellectual,
depressed mood, somatic complaints, muscular or
somatic complaints, sensory, cardiovascular symptoms,
respiratory symptoms, gastrointestinal symptoms, gen-
itourinary symptoms, autonomic symptoms, and behav-
iour during the interview [31]. A global score greater
than 20 is usually required for inclusion into therapeutic
trials. The authors consider two sub-scales: psychic
anxiety (items 1–6 and 14) and somatic anxiety (items
7–13, underlined supra).
3. Quality of life was evaluated by using the SF-36, a
self-administered, 36-item questionnaire that measures
health-related functions in eight domains : physical
Table 1 Description of our
sub-groups












8 43 18 37
Age (years) 46.5 (17.2) 44.0 (15.2) 47.3 (19.4) 50.3 (13.1)
Female/male 8/0 33/10 12/6 24/13
Body mass index 23.1 (3.4) 18.6 (4.6) 22.8 (3.2) 23.9 (4.8)
Life event impact Amiel
Lebigre score
477.5 (288.6) 362 (478.7) 243.3 (309) 203.9 (238.7)
Pain intensity index 52.0 (12.3) 61.8 (22.3) 40.7 (15.8) 47.4 (16.3)
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functioning (PF), role physical (RP), body pain (BP),
general health perception (GH), vitality (VT), social
functioning (SF), role emotional (RE), and mental
health (MH) [32]; data from a control population,
adjusted for gender and age, are reported in Table 3
[33]. These domains are summarised by the mental
component summary (MCS) and the physical compo-
nent summary (PCS) which are loaded differently from
the height domain sub-scores; the score of these mental
and physical component summaries is about 50 [34] in
a control population.
Statistical methods
To limit the number of comparisons, we selected five vari-
ables which are widely used in the literature: the MADRS
global score, the two HAMA sub-scales (HAMA psy,
HAMA phy), and the two SF 36 dimension MCS and PCS.
Due to the different number of patients in each sub-
groups, we carefully pooled our study patients in two dif-
ferent groups according to the clinical type of headache i.e.
patients with migraine symptoms versus patients with ten-
sion-type symptoms by pooling CM and mMOH patients
into a migraine group (n = 51) and CTT and ttMOH patients
into a tension-type group (n = 55). To exclude pain inten-
sity, which is a predicted confusion-factor, we used an
ANCOVA to control the pain index, after testing for the non-
heterogeneity of the variance with a Levene’s test. When
significant differences were present, we performed further
explanatory comparisons using the same methodology.
Results (Tables 1 and 2)
The MARDS mean global score was less than 20 in each of
the four sub-groups and did not differ significantly between
the migraine and tension-type groups (see details in Table 2).
The HAMA mean global score was high in CM
(21.6 ± 9.0) and remained below 20 in CTTH (15.6 ± 9.7),
mMOH (16.3 ± 8.5), and in ttMOH (12.4 ± 7.5) sub-
groups. The HAMA psychological and somatic sub-scores
are reported in Table 2. These sub-scores were constantly
higher in CM and mMOH than in CTTH and ttMOH sub--
groups. However, the statistical comparison between the
migraine and tension-type groups showed a significant dif-
ference only for the somatic HAMA subscale (p = 0.001 see
Table 2).
The SF 36 physical and mental component summary
scores are reported in Table 2. Scores were always lower
(therefore the patients were more disabled) in the CM sub-
group and all the scores were lower than the scores seen in
the general population (which is about 50): comparison
between migraine and tension-type groups revealed that the
mental component summary was lower in the migraine
group (p = 0.018 see Table 2).
To explain these differences, we considered the eight
SF36 domain scores according to clinical sub-groups (see
Table 3). With the exception of physical functioning, sub-
scale scores were often 20 points lower than control scores
and were constantly lower in the CM sub-group. However,
comparison between tension-type and migraine groups
only revealed significant differences in two domains, which
were lower in the migraine group: mental health (MH,
p = 0.005) and bodily pain (BP, p = 0.036)
Discussion
Our data focus on the fact that, among patients who suffer
from chronic daily headache, there is a difference between
patients with migraine symptoms and those with tension-
type headache symptoms. Our data indicate that the ten-
dency towards anxiety, already reported in chronic daily
headache, is mostly manifested by the somatic symptoms
reported by patients with migraine symptoms whether or
not they are drug-abusers. Indeed, the HAMA somatic sub-
scale, which is significantly different in patients with and
without migraine symptoms, is composed of seven items
related to somatic symptoms (two general somatic, one
cardiovascular, one respiratory, one gastro-intestinal, one
sexual and urinary, and one autonomic). This propensity
for headache patients to express somatic symptoms had
been already reported with other psychological tools [35,
36]; our data suggest that in the whole group of CDH, the
anxiety increase is rather due to the somatic anxiety of the
patients with migraine symptoms. This raises the following
questions: do migraine symptoms have a particular pro-
pensity to induce somatic anxiety, or does somatic anxiety
increase the occurrence of a migraine symptoms? Inter-
estingly our data do not suggest a high level of somatic and
psychological anxiety in the two subgroups with medica-
tion overuse (see Table 2), which lead to discuss two
hypothesis: either a special trait of MOH patients or, an
anxiolytic effect of the drug abuse itself.
The raw SF 36 height domain data suggest that all cate-
gories of chronic daily headache patients have an excessively
low quality of life. In our cohort as well as in others’ [17, 37],
all domains of the SF 36 except one (physical functioning)
were significantly affected in the four groups of patients; in
addition, the mean scores were often 20 to 40 points different
from the scores in historical controls (Table 3). It is not
surprising that the Physical Functioning score, which is the
result of 10 questions mainly concerned with purely motor
performances, is the least-affected domain. Our data strongly
suggest a high burden since in this test, a five point difference
250 J Headache Pain (2010) 11:247–253
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is considered clinically or socially relevant [38]. The control
group is based on data obtained from the Oxford Healthy Life
Survey (13,042 subjects between 18 and 64 years old,
response rate 72% (see details in Ref. [34]). We adjusted the
normative data for gender and age in our study. The severity
of the quality of life impairment is also suggested by the
historical comparison of SF 36 performed in epileptic
patients who reported more than one seizure per month [39]
and who seemed to be less affected in all domains.
When considering the impairment in global quality of
life, the SF36 mental domain and more precisely, the
mental health and the bodily pain dimensions are signifi-
cantly more impaired in patients with migraine symptoms
than in those with tension-type symptoms. Bodily Pain may
be considered to represent a measure of the discomfort
induced by repeated pain and Mental Health as the inability
to feel that one has a healthy psychic functioning. These
data are worth considering since the factor intensity of pain
is supposedly neutralised by the statistical procedure. One
interpretation could be that, confronted with a pain of
equivalent intensity, migraine patients are particularly
vulnerable as compared to tension-type patients. If we
integrate our data with the biological–psychological–social
framework of headache as developed by Nicholson et al.
[40], we can also hypothesise that among chronic daily
headache patients, those with migraine symptoms may
have either a greater predisposition to developing negative
pain-related affects, or an higher vulnerability to quality of
life discomfort.
Some aspects of our study deserve confirmation in future
studies. Previous stressful life events may be more prevalent
in CM patients and may deserve to be specifically studied.
Previous psychiatric disorders need to be analysed with a
systematic and comprehensive tool. The depressive ten-
dency of our patients, evaluated by the mean MADRS
score, did not reach a level usually considered to represent
overt pathology [41] in each sub-groups. This data differ
from Mitsikostas and Thomas findings [13]; they compared
several headache sufferer subsets and found that the ‘‘drug
abuse headache group’’ had the highest mean score in the
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31.4 ± 8.3 35.5 ± 11.1 41.8 ± 10.8 41.3 ± 11.8 5.758
p = 0.018














(1 ? 3) versus tension type
(2 ? 4) F(1,103)
Physical functioning 91.6 70.0 (24.6) 84.2 (21.9) 79.5 (22.0) 83.5 (12.0) 1.25 ns
Role limitation physical 87.9 31.2 (29.1) 58.33 (7.4) 49.4 (42.4) 56.9 (34.1) 0.39 ns
Bodily pain 83.8 30.3 (10.3) 47.1 (12.1) 39.1 (16.7) 48.9 (18) 4.51 p = 0.036
General health perception 73.8 43.0 (14.2) 49.8 (20.0) 53.0 (19.6) 54.5 (18.9) 0.01 ns
Vitality 61.9 34.3 (11.4) 55.0 (18.7) 41.3 (20.2) 48.3 (18.8) 2.92 ns
Social functioning 89.4 51.6 (19.4) 60.4 (30.1) 53.8 (27.1) 67.0 (26.1) 2.42 ns
Role limitation emotional 84.3 41.7 (34.5) 61.1 (40.0) 47.3 (41.9) 64.8 (37.0) 3.04 ns
Mental health 74 31.0 (10.8) 58.9 (15.7) 47.5 (16.6) 56.4 (18.4) 8.17 p = 0.005
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Hamilton Depression Scale and even reached a pathological
level. This point is important if we consider that some
previously cited reports showed an increase in mood dis-
orders in CDH [10, 11, 14]. The level of medication overuse
may account for part of these apparent discrepancies: the
patients of our group were included according to the most
recent ICHD 2004/2006(code 8.2) definition, which
requires a regular intake of opiates alone or in combination
for 10 days/month or more and for 15 days/month or more
when other analgesics are taken. The patients in the previ-
ous cohorts had a more frequent medication intake since
they were recruited either according to the 1988 IHS clas-
sification (code 8.2-4) [42] in which daily analgesic use is
mandatory or when they took drugs for 18 days/month or
more [15]. It seems likely that when drug abuse is greater,
the mean depressive level is higher.
Our study is limited by some methodological drawbacks
which need to be discussed. Our selected and heteroge-
neous cohort can hardly be considered to represent CDH in
the general population, but we may hypothesise that the
psychopathological problems reported by patients in our
study cohort somewhat reflect the psychopathological
problems seen in CDH patients in general, whatever the
mode of selection. Selecting purely CM patients is difficult
since they often abuse medication; specific studies are
needed in this sub-group since their scores were highly
pathological if we consider the scores they obtained in all
the evaluation scales. The use of spontaneous patient recall,
which induces an obvious bias in historical items and the
number of days with a given type of headache combined
with the small size of the CM group, suggests that this
study needs to be repeated with a larger patient cohort and
the use of a diary before inclusion. The overlap of a limited
number of patients does not invalidate our study although it
does reduce the strength of the analysis.
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